Efficacy and Safety of Aripiprazole in Patients With Schizophrenia or Bipolar Disorder

Last updated: October 22, 2013
Sponsor: Korea Otsuka Pharmaceutical Co., Ltd.
Overall Status: Completed

Phase

N/A

Condition

Bipolar Disorder

Tourette's Syndrome

Mood Disorders

Treatment

N/A

Clinical Study ID

NCT00216723
Korea Abilify PMS
  • Ages 18-80
  • All Genders

Study Summary

This is a multicenter,open-label,prospective study of Aripiprazole use in patients with schizophrenia and bipolar disorder.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patient with a schizophrenia or schizoaffective disorder or bipolar disorder accordingto DSM-IV criteria

  • Age: more than 18 years of age

Exclusion

Exclusion Criteria:

  • Unqualified patients judged by study investigator(s)

Study Design

Total Participants: 3000
Study Start date:
April 01, 2004
Estimated Completion Date:
December 31, 2009

Study Description

This is a multicenter,open-label,prospective study of Aripiprazole use in patients with schizophrenia and bipolar disorder.

Qualified schizophrenia patients will be enrolled to an 12-week treatment phase of Aripiprazole by physician's assessment.

Qualified bipolar disorder patients will be enrolled to an 8-week treatment phase of Aripiprazole by physician's assessment.

This study will be continued for 6 years. The final report of Aripiprazole PMS will be submitted to KFDA on December 28, 2009.

Connect with a study center

  • Asan Medical Center

    Seoul,
    Korea, Republic of

    Site Not Available

  • Samsung Medical Center

    Seoul,
    Korea, Republic of

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.